Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

REUBEN MARI VALENZUELA

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1922328103
CMS profile
87116
Location
PEORIA, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$94,679.80

156 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 156 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

REUBEN MARI VALENZUELA

NPI 1922328103 · CMS profile ID 87116

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

PEORIA, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 156 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1922328103?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
REUBEN MARI VALENZUELA, NPI 1922328103, CMS profile ID 87116. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 156 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1922328103?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). REUBEN MARI VALENZUELA, NPI 1922328103, CMS profile ID 87116. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 156 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1922328103?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
REUBEN MARI VALENZUELA, NPI 1922328103, CMS profile ID 87116, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 156 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1922328103?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

156 matching records · $94,679.80 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 156 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 156.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Supernus Pharmaceuticals, Inc. $21.9806/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845126665 CMS
Amgen Inc. $19.9206/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825715959 CMS
Genentech USA, Inc. $2,060.0006/22/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835966445 CMS
Alexion Pharmaceuticals, Inc. $960.0006/16/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783114415 CMS
Lundbeck LLC $16.9806/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845938975 CMS
Biogen, Inc. $1,395.0006/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827854775 CMS
EMD Serono, Inc. $42.9506/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849192601 CMS
Celgene Corporation $21.2206/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783680863 CMS
Novartis Pharmaceuticals Corporation $23.2406/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813331937 CMS
UCB, Inc. $14.9106/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807360551 CMS
Alexion Pharmaceuticals, Inc. $600.0006/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783114485 CMS
Biogen, Inc. $2,790.0006/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827854773 CMS
Biogen, Inc. $79.2906/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827854783 CMS
Biogen, Inc. $2,790.0006/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827854791 CMS
EMD Serono, Inc. $400.0006/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849181127 CMS
SANOFI-AVENTIS U.S. LLC $19.4806/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843652335 CMS
AbbVie Inc. $15.2005/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796191891 CMS
Celgene Corporation $13.3405/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783680853 CMS
Biohaven Pharmaceuticals, Inc. $13.6205/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852647455 CMS
Biogen, Inc. $8.9005/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827854809 CMS
Amgen Inc. $11.7805/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825715955 CMS
EMD Serono, Inc. $68.1605/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849190822 CMS
GENZYME CORPORATION $1,638.0005/11/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843652387 CMS
Celgene Corporation $8.1505/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783680851 CMS
AbbVie Inc. $18.8805/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796191889 CMS
Novartis Pharmaceuticals Corporation $66.0704/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813331905 CMS
Biohaven Pharmaceuticals, Inc. $12.8604/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852647453 CMS
SK Life Science, Inc. $6.3004/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826849767 CMS
Biogen, Inc. $2,480.0004/16/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827854793 CMS
Janssen Pharmaceuticals, Inc $1,500.0004/14/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788828269 CMS
Novartis Pharmaceuticals Corporation $21.0404/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813331929 CMS
EMD Serono, Inc. $1,400.0003/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849180289 CMS
Amgen Inc. $20.9803/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825715947 CMS
GENZYME CORPORATION $1,911.0003/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843652307 CMS
Alexion Pharmaceuticals, Inc. $1,200.0003/18/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783114419 CMS
Biogen, Inc. $11.1303/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827854807 CMS
Biogen, Inc. $1,395.0003/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827854771 CMS
Alexion Pharmaceuticals, Inc. $16.6703/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783114409 CMS
Lilly USA, LLC $13.6403/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818731071 CMS
Biohaven Pharmaceuticals, Inc. $16.4003/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852647451 CMS
Novartis Pharmaceuticals Corporation $7.6503/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813331933 CMS
Adamas Pharmaceuticals, Inc. $22.5403/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834405377 CMS
Genentech USA, Inc. $24.8902/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835966449 CMS
E.R. Squibb & Sons, L.L.C. $14.5202/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783448131 CMS
Stryker Corporation $14.9402/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 806699545 CMS
Mallinckrodt Hospital Products Inc. $21.4502/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845383857 CMS
Alexion Pharmaceuticals, Inc. $960.0002/05/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783114429 CMS
Biogen, Inc. $162.4002/05/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827854821 CMS
Biogen, Inc. $3,255.0002/05/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827854823 CMS
E.R. Squibb & Sons, L.L.C. $13.9802/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783448117 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $41,973.56 123
PY2020 $44,503.62 94
PY2021 $94,679.80 156
PY2022 $129,181.43 181
PY2023 $76,162.77 210
PY2024 $78,312.94 234
PY2025 $125,131.62 273

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $21,191.75 14
PY2024 Principal investigator $114,645.27 40
PY2023 Principal investigator $65,723.60 44
PY2022 Principal investigator $68,916.60 62
PY2021 Principal investigator $22,628.75 36
PY2020 Principal investigator $55,553.84 53
PY2019 Principal investigator $22,813.14 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

14 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 EMD Serono, Inc. $345.00 09/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118191
Principal investigator 1 EMD Serono, Inc. $1,200.00 09/09/2025 Non-covered Recipient Entity
PRAIRIE EDUCATION AND RESEARCH COOPERATIVE
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118465
Principal investigator 1 GENZYME CORPORATION $15,262.75 09/08/2025 Non-covered Recipient Entity
Springfield Clinic Llp
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226081556
Principal investigator 1 GENZYME CORPORATION $65.00 08/25/2025 Non-covered Recipient Entity
Springfield Clinic Llp
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226081559
Principal investigator 1 GENZYME CORPORATION $260.00 08/25/2025 Non-covered Recipient Entity
Springfield Clinic Llp
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226081564
Principal investigator 1 GENZYME CORPORATION $180.00 08/25/2025 Non-covered Recipient Entity
Springfield Clinic Llp
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226081568
Principal investigator 1 GENZYME CORPORATION $65.00 08/25/2025 Non-covered Recipient Entity
Springfield Clinic Llp
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226081572
Principal investigator 1 GENZYME CORPORATION $180.00 08/25/2025 Non-covered Recipient Entity
Springfield Clinic Llp
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226081576
Principal investigator 1 GENZYME CORPORATION $65.00 08/25/2025 Non-covered Recipient Entity
Springfield Clinic Llp
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226081582
Principal investigator 1 GENZYME CORPORATION $65.00 08/25/2025 Non-covered Recipient Entity
Springfield Clinic Llp
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226081586
Principal investigator 1 EMD Serono, Inc. $1,345.00 05/22/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118195
Principal investigator 1 GENZYME CORPORATION $375.00 04/02/2025 Non-covered Recipient Entity
Springfield Clinic Llp
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226081478
Principal investigator 1 EMD Serono, Inc. $1,280.00 03/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118199
Principal investigator 1 EMD Serono, Inc. $504.00 03/18/2025 Non-covered Recipient Entity
PRAIRIE EDUCATION AND RESEARCH COOPERATIVE
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118463